Search
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigationalPatients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body. … Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder.
Onapristone
go.drugbank.com/drugs/DB12637InvestigationalTumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy. … Onapristone has been used in trials studying the treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive
Vonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigational[A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection. … Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H<sup>+</sup>, K<sup>+</sup>-ATPase-mediated gastric acid secretion.
Synonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamineBempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigationalAzacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]
Synonyms: 4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-oneVoxelotor
go.drugbank.com/drugs/DB14975ApprovedThis is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: ANAGRELID AL 0.5MG HKPSulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Prasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalSimilar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. … FDA approved in 2009.
Products: PRASUGREL AL 5MG HBR FTA, PRASUGREL AL 10MG HBR FTAForasartan
go.drugbank.com/drugs/DB01342ExperimentalAs angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. … Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension.
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor Blockers